IGF-1 LR3
← Back to LibraryOverview
Route(s): Subcutaneous
Typical vial sizes: 1 mg
Dosing window: Post-Workout
Receptor / target: IGF-1
Properties: Not stated
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 33mcg daily | 1x/day, 7 days per week. Dose immediately post-workout (within 30 mins) with carbs and protein. |
| Week 2 | 50mcg daily | 1x/day, 7 days per week. Avoid taking at bedtime or while fasted. |
| Weeks 3-4 | 75mcg daily | 1x/day, 7 days per week. Ensure adequate calories/protein are consumed. |
| Weeks 5-8 | 100mcg daily | 1x/day, 7 days per week. Maximum recommended dosage phase. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative: Bilateral IM
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 50mcg split (25mcg per side) | Administered intramuscularly into the trained muscle group (e.g., left and right bicep) immediately post-workout. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Independent evidence
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Active cancer: IGF-1 is a potent mitogen; direct IGF-1 receptor activation accelerates proliferation of malignant cells.
- History of malignancy: especially hormone-sensitive cancers; IGF-1 receptor signaling drives tumor growth in breast, prostate, and colorectal cancers.
- Hypoglycemia or hypoglycemia unawareness: acute hypoglycemia is the primary risk; IGF-1 receptor activity mimics insulin; never administer fasted.
- Diabetic ketoacidosis.
- Type 1 or insulin-dependent diabetes: IGF-1's insulin-like activity requires careful glycemic management.
- Concurrent use with insulin: severe additive hypoglycemia risk; extreme caution required.
- Concurrent administration without food: administration without concurrent carbohydrates and protein is contraindicated; hypoglycemia risk is immediate.
- Pre-existing visceral organ enlargement: IGF-1 at high doses drives growth in all IGF-1 receptor-expressing tissues, including intestinal epithelium and visceral organs.
- Active acromegaly: additive IGF-1 receptor stimulation in a state of existing IGF-1 excess.
- Pregnancy: IGF-1 analog activity not established in pregnancy; potential fetal risk.
- Breastfeeding: safety not established.
- Known hypersensitivity to IGF-1 LR3 or excipients.
- Pediatric use: safety and efficacy not established; open growth plates in children risk inappropriate and disproportionate skeletal growth.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Severe hypoglycemia: the most critical adverse effect; direct insulin-like glucose uptake via IGF-1 receptor activation; onset typically 30-60 minutes post-injection; more pronounced with fasted administration; always administer with carbohydrates present.
- Intestinal growth and gut hypertrophy: with abused long-term or excessive dosing, IGF-1 receptor stimulation in gastrointestinal epithelium can cause measurable organ enlargement; this is the primary long-term misuse risk.
- Visceral organ growth: liver, spleen, kidneys; IGF-1 receptor is expressed in all visceral organs; supraphysiologic IGF-1 exposure over extended periods may drive size increases.
- Localized swelling at injection site: tissue response to subcutaneous or intramuscular injection.
- Edema: IGF-1-mediated sodium and fluid retention.
- Jaw tightening or facial growth (at high doses/extended abuse): IGF-1 receptors in craniofacial tissues; acromegalic-type effects at very high doses.
- Joint pain: GH/IGF-1 axis-mediated periarticular fluid.
- Headache.
- Fatigue: transient post-injection.
- Nausea: dose-dependent.
- Increased appetite: orexigenic effect of IGF-1 receptor activity.
- Tingling or numbness in extremities: insulin-like effects and fluid shifts.
- Carpal tunnel syndrome risk: with extended high-dose use.
- Downregulation of endogenous GH production: negative feedback from elevated IGF-1 on hypothalamic-pituitary axis; natural GH production suppressed during and after long cycles.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.